Pancreatic ductal adenocarcinoma: biological hallmarks, current status, and future perspectives of combined modality treatment approaches
M Orth, P Metzger, S Gerum, J Mayerle, G Schneider… - Radiation …, 2019 - Springer
Pancreatic ductal adenocarcinoma (PDAC) is a highly devastating disease with poor
prognosis and rising incidence. Late detection and a particularly aggressive biology are the …
prognosis and rising incidence. Late detection and a particularly aggressive biology are the …
Metabolism of pancreatic cancer: paving the way to better anticancer strategies
C Qin, G Yang, J Yang, B Ren, H Wang, G Chen… - Molecular cancer, 2020 - Springer
Pancreatic cancer is currently one of the most lethal diseases. In recent years, increasing
evidence has shown that reprogrammed metabolism may play a critical role in the …
evidence has shown that reprogrammed metabolism may play a critical role in the …
Efficacy of a Small-Molecule Inhibitor of KrasG12D in Immunocompetent Models of Pancreatic Cancer
SB Kemp, N Cheng, N Markosyan, R Sor, IK Kim… - Cancer discovery, 2023 - AACR
Mutations in the KRAS oncogene are found in more than 90% of patients with pancreatic
ductal adenocarcinoma (PDAC), with Gly-to-Asp mutations (KRAS G12D) being the most …
ductal adenocarcinoma (PDAC), with Gly-to-Asp mutations (KRAS G12D) being the most …
Durvalumab with or without tremelimumab for patients with metastatic pancreatic ductal adenocarcinoma: a phase 2 randomized clinical trial
EM O'Reilly, DY Oh, N Dhani, DJ Renouf… - JAMA …, 2019 - jamanetwork.com
Importance New therapeutic options for patients with metastatic pancreatic ductal
adenocarcinoma (mPDAC) are needed. This study evaluated dual checkpoint combination …
adenocarcinoma (mPDAC) are needed. This study evaluated dual checkpoint combination …
Sialic acids in pancreatic cancer cells drive tumour-associated macrophage differentiation via the Siglec receptors Siglec-7 and Siglec-9
E Rodriguez, K Boelaars, K Brown… - Nature …, 2021 - nature.com
Abstract Changes in glycosylation during tumour progression are a key hallmark of cancer.
One of the glycan moieties generally overexpressed in cancer are sialic acids, which can …
One of the glycan moieties generally overexpressed in cancer are sialic acids, which can …
Targeting the bicarbonate transporter SLC4A4 overcomes immunosuppression and immunotherapy resistance in pancreatic cancer
Solid tumors are generally characterized by an acidic tumor microenvironment (TME) that
favors cancer progression, therapy resistance and immune evasion. By single-cell RNA …
favors cancer progression, therapy resistance and immune evasion. By single-cell RNA …
The CCTG PA. 7 phase II trial of gemcitabine and nab-paclitaxel with or without durvalumab and tremelimumab as initial therapy in metastatic pancreatic ductal …
Immunotherapy-based monotherapy treatment in metastatic pancreatic ductal
adenocarcinoma (mPDAC) has shown limited benefit outside of the mismatch repair …
adenocarcinoma (mPDAC) has shown limited benefit outside of the mismatch repair …
[HTML][HTML] Nanocarriers for pancreatic cancer imaging, treatments, and immunotherapies
Pancreatic tumors are highly desmoplastic and immunosuppressive. Delivery and
distribution of drugs within pancreatic tumors are compromised due to intrinsic physical and …
distribution of drugs within pancreatic tumors are compromised due to intrinsic physical and …
[HTML][HTML] Simultaneous targeting of PD-1 and IL-2Rβγ with radiation therapy inhibits pancreatic cancer growth and metastasis
M Piper, M Hoen, LB Darragh, MW Knitz, D Nguyen… - Cancer Cell, 2023 - cell.com
In pancreatic ductal adenocarcinoma (PDAC) patients, we show that response to radiation
therapy (RT) is characterized by increased IL-2Rβ and IL-2Rγ along with decreased IL-2Rα …
therapy (RT) is characterized by increased IL-2Rβ and IL-2Rγ along with decreased IL-2Rα …
Immunosuppression, immune escape, and immunotherapy in pancreatic cancer: focused on the tumor microenvironment
YH Zhu, JH Zheng, QY Jia, ZH Duan, HF Yao, J Yang… - Cellular Oncology, 2023 - Springer
Pancreatic ductal adenocarcinoma (PDAC), the most common type of pancreatic cancer, is
characterized by poor treatment response and low survival time. The current clinical …
characterized by poor treatment response and low survival time. The current clinical …